Financials data is unavailable for this security.
View more
Year on year Kaken Pharmaceutical Co Ltd had relatively flat revenues (72.98bn to 72.04bn), though the company grew net income 47.54% from 5.44bn to 8.03bn.
| Gross margin | 60.66% |
|---|---|
| Net profit margin | 20.91% |
| Operating margin | 26.24% |
| Return on assets | 10.17% |
|---|---|
| Return on equity | 12.36% |
| Return on investment | 11.66% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at Kaken Pharmaceutical Co Ltd fell by 8.94bn. However, the company earned 2.58bn from its operations for a Cash Flow Margin of 3.58%. In addition the company used 5.85bn on investing activities and also paid 5.66bn in financing cash flows.
| Cash flow per share | 551.70 |
|---|---|
| Price/Cash flow per share | 9.64 |
| Book value per share | 4,076.80 |
|---|---|
| Tangible book value per share | 3,882.05 |
More ▼
Balance sheet in JPYView more
| Current ratio | 5.18 |
|---|---|
| Quick ratio | 4.47 |
| Total debt/total equity | 0.0249 |
|---|---|
| Total debt/total capital | 0.0243 |
More ▼
Growth rates in JPY
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 46.87%. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is below the industry average.
| Div yield(5 year avg) | 3.67% |
|---|---|
| Div growth rate (5 year) | 0.00% |
| Payout ratio (TTM) | 39.51% |
| EPS growth(5 years) | -13.76 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 410.88 |
More ▼
